|
|
Article: Schering-Plough Announces CLARINEX(R) (desloratadine) Tablets Approved for Allergic Rhinitis and Chronic Idiopathic Urticaria; First Nonsedating Antihistamine for Both Indoor and Outdoor Allergies; CLARINEX Has Broadest Indications of Any Nonsedating Antihistamine.
- Article from:
- PR Newswire
- Article date:
- February 11, 2002
CopyrightCOPYRIGHT 2002 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
KENILWORTH, N.J. -- Schering-Plough Corporation announced today that its new antihistamine CLARINEX(R) (desloratadine) 5 mg Tablets has been granted the broadest indications of any nonsedating antihistamine. CLARINEX is the first and only nonsedating antihistamine approved by the U.S. Food and Drug Administration (FDA) to treat the symptoms of allergies caused by indoor and outdoor allergens in adults and children 12 years of age and older. The company said the FDA also approved CLARINEX Tablets for the treatment of chronic idiopathic urticaria (CIU), or hives of unknown cause, in the same age group.
CLARINEX labeling has been broadened to include the treatment ...